Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GSK3277511A NTHi-Mcat vaccine schedules in adults with COPD
2017-002941-31Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GSK3277511A in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Solicited local adverse events. Started Oct 2017; status: completed.
02
Drugs
GSK3277511A
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-002941-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002941-31.